Cargando…

Modification of meta-iodobenzylguanidine uptake in neuroblastoma cells by elevated temperature.

Successful imaging or treatment of neuroblastoma with 131I-meta-iodobenzylguanidine (131I-mIBG) depends on the selectivity of active (type 1) uptake of mIBG in neuroblastoma cells relative to passive (type 2) uptake present in most normal tissues. This study investigates the effects of moderately el...

Descripción completa

Detalles Bibliográficos
Autores principales:	Armour, A., Mairs, R. J., Gaze, M. N., Wheldon, T. E.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1994
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033365/ https://www.ncbi.nlm.nih.gov/pubmed/8080728

Ejemplares similares

131I-meta-iodobenzylguanidine therapy in neuroblastoma spheroids of different sizes.
por: Gaze, M. N., et al.
Publicado: (1992)

Prediction of accumulation of 131I-labelled meta-iodobenzylguanidine in neuroblastoma cell lines by means of reverse transcription and polymerase chain reaction.
por: Mairs, R. J., et al.
Publicado: (1994)

The effect of cisplatin pretreatment on the accumulation of MIBG by neuroblastoma cells in vitro.
por: Armour, A., et al.
Publicado: (1997)

The uptake and retention of metaiodobenzyl guanidine by the neuroblastoma cell line NB1-G.
por: Mairs, R. J., et al.
Publicado: (1991)

Selective serotonin reuptake inhibitors (SSRIs) prevent meta-iodobenzylguanidine (MIBG) uptake in platelets without affecting neuroblastoma tumor uptake
por: Blom, Thomas, et al.
Publicado: (2020)

A model of modified meta-iodobenzylguanidine conjugated gold nanoparticles for neuroblastoma treatment
por: Saimuang, Kween, et al.
Publicado: (2021)

Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters
por: Kölby, L, et al.
Publicado: (2003)

Radiosynthesis of no-carrier-added meta-[(124)I]iodobenzylguanidine for PET imaging of metastatic neuroblastoma
por: Green, Michael, et al.
Publicado: (2016)

Thrombocytopenia after meta-iodobenzylguanidine (MIBG) therapy in neuroblastoma patients may be caused by selective MIBG uptake via the serotonin transporter located on megakaryocytes
por: Blom, Thomas, et al.
Publicado: (2021)

(123)I-Meta-Iodobenzylguanidine Single-Photon Emission Computerized Tomography/Computerized Tomography Scintigraphy in the Management of Neuroblastoma
por: Biassoni, Lorenzo, et al.
Publicado: (2021)

Toxicity to neuroblastoma cells and spheroids of benzylguanidine conjugated to radionuclides with short-range emissions.
por: Cunningham, S. H., et al.
Publicado: (1998)

Diagnostic Use of Post-therapy (131)I-Meta-Iodobenzylguanidine Scintigraphy in Consolidation Therapy for Children with High-Risk Neuroblastoma
por: Wakabayashi, Hiroshi, et al.
Publicado: (2020)

An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma
por: Nile, Donna L., et al.
Publicado: (2016)

A convenient Simple Method for Synthesis of Meta-iodobenzylguanidine (MIBG)
por: Sheikholislam, Zahra, et al.
Publicado: (2013)

The distribution of alternative agents for targeted radiotherapy within human neuroblastoma spheroids.
por: Mairs, R. J., et al.
Publicado: (1991)

Inhibition of glycolysis and mitochondrial respiration promotes radiosensitisation of neuroblastoma and glioma cells
por: Nile, Donna L., et al.
Publicado: (2021)

An evaluation in vitro of the efficacy of nutlin-3 and topotecan in combination with (177)Lu-DOTATATE for the treatment of neuroblastoma
por: Tesson, Mathias, et al.
Publicado: (2018)

(123)I-Meta-iodobenzylguanidine Sympathetic Imaging: Standardization and Application to Neurological Diseases
por: Nakajima, Kenichi, et al.
Publicado: (2016)

Reproducibility of planar (123)I-meta-iodobenzylguanidine (MIBG) myocardial scintigraphy in patients with heart failure
por: Veltman, Caroline E., et al.
Publicado: (2012)

Biomarker response to high-specific-activity I-131 meta-iodobenzylguanidine in pheochromocytoma/paraganglioma
por: Jimenez, Camilo, et al.
Publicado: (2022)

Bioavailability and toxicity after oral administration of m-iodobenzylguanidine (MIBG)
por: Kuin, A, et al.
Publicado: (1999)

Standardization of (123)I-meta-iodobenzylguanidine myocardial sympathetic activity imaging: phantom calibration and clinical applications
por: Nakajima, Kenichi, et al.
Publicado: (2017)

A novel approach in the treatment of neuroendocrine gastrointestinal tumors: Additive antiproliferative effects of interferon-γ and meta-iodobenzylguanidine
por: Höpfner, Michael, et al.
Publicado: (2004)

Diagnostic Accuracy of (123)I-Meta-Iodobenzylguanidine Myocardial Scintigraphy in Dementia with Lewy Bodies: A Multicenter Study
por: Yoshita, Mitsuhiro, et al.
Publicado: (2015)

Cross calibration of (123)I-meta-iodobenzylguanidine heart-to-mediastinum ratio with D-SPECT planogram and Anger camera
por: Nakajima, Kenichi, et al.
Publicado: (2017)

A phase I clinical trial for [(131)I]meta-iodobenzylguanidine therapy in patients with refractory pheochromocytoma and paraganglioma
por: Wakabayashi, Hiroshi, et al.
Publicado: (2019)

Validation of 2-year (123)I-meta-iodobenzylguanidine-based cardiac mortality risk model in chronic heart failure
por: Nakajima, Kenichi, et al.
Publicado: (2018)

Clonality analysis suggests that early-onset acute lymphoblastic leukaemia is of single-cell origin and implies no major role for germ cell mutations in parents
por: Rinaldi, F, et al.
Publicado: (1999)

Prediction of Long-term Cardiac Events by 123I-meta-Iodobenzylguanidine Imaging after acute Myocardial Infarction and Reperfusion Therapy
por: Nakamura, Manabu, et al.
Publicado: (2019)

Iodine-123-meta-iodobenzylguanidine Myocardial Scintigraphy in Isolated Autonomic Failure: Potential Red Flag for Future Multiple System Atrophy
por: Baschieri, Francesca, et al.
Publicado: (2017)

Author Correction: A phase I clinical trial for [(131)I]meta-iodobenzylguanidine therapy in patients with refractory pheochromocytoma and paraganglioma
por: Wakabayashi, Hiroshi, et al.
Publicado: (2022)

New MIBG preparation to improve targeted radiotherapy and reduce toxic side-effects in neuroblastoma patients undergoing combination treatment.
por: Mairs, R. J., et al.
Publicado: (1995)

Cost-Effectiveness Analysis of Iodine-123 Meta-Iodobenzylguanidine Imaging for Screening Heart Failure Patients Eligible for an Implantable Cardioverter Defibrillator in the USA
por: O’Day, Ken, et al.
Publicado: (2016)

Impact of Diabetes on Cardiac Sympathetic Innervation in Patients With Heart Failure: A (123)I meta-iodobenzylguanidine ((123)I MIBG) scintigraphic study
por: Paolillo, Stefania, et al.
Publicado: (2013)

CUDC-907, a dual PI3K/histone deacetylase inhibitor, increases meta-iodobenzylguanidine uptake ((123/131)I-mIBG) in vitro and in vivo: a promising candidate for advancing theranostics in neuroendocrine tumors
por: Grand-Guillaume, Joana, et al.
Publicado: (2023)

The uptake of alpha-foetoprotein by C-1300 mouse neuroblastoma cells.
por: Hajeri-Germond, M., et al.
Publicado: (1985)

Creation of mortality risk charts using (123)I meta-iodobenzylguanidine heart-to-mediastinum ratio in patients with heart failure: 2- and 5-year risk models
por: Nakajima, Kenichi, et al.
Publicado: (2016)

Differential cytotoxicity of [123I]IUdR, [125I]IUdR and [131I]IUdR to human glioma cells in monolayer or spheroid culture: effect of proliferative heterogeneity and radiation cross-fire.
por: Neshasteh-Riz, A., et al.
Publicado: (1998)

An open-label, single-arm, multi-center, phase II clinical trial of single-dose [(131)I]meta-iodobenzylguanidine therapy for patients with refractory pheochromocytoma and paraganglioma
por: Inaki, Anri, et al.
Publicado: (2021)

Biological properties of a tumour cell line (NB1-G) derived from human neuroblastoma.
por: Carachi, R., et al.
Publicado: (1987)

Cannot write session to /tmp/vufind_sessions/sess_vv77290vj9h3sf0ksjp124gk1m